Navegando por Autor "ABDON, Nagib Ponteira"

Agora exibindo 1 - 2 de 2

Acesso aberto (Open Access)
Avaliação da resposta aos esquemas de tratamento reduzidos para malária vivax
(Universidade Federal do Pará, 2001-08) ABDON, Nagib Ponteira; PINTO, Ana Yecê das Neves; SILVA, Rita do Socorro Uchôa da; SOUZA, José Maria de
Relapses may occur with long standard treatment of vivax malaria, and these are caused by incomplete patient’s compliance. The use of reduced schedules may further better patient compliance, while maintaining the same efficacy, tolerance and minimal adverse reactions. The objective of this study was to test two schedules with reduced doses of chloroquine for vivax malaria and comparing these with the classical schedule. The authors studied 120 outpatients, with vivax malaria, aged over 12 years, submitted to three therapeutic schemes: scheme I: chloroquine phosphate (150mg) in a dose of 25mg/kg/day for three days (10mg/kg/ day in the first day, 7.5mg/kg/day in the second and third day), plus primaquine (15mg) in a dose of 0.25mg/kg/day for fourteen days; scheme II: chloroquine, in a single dose of 10mg/kg, plus primaquine in a dose of 0.5mg/kg/day for seven days; scheme III: chloroquine, 10mg/kg in a single dose plus primaquine in a dose 0.5mg/kg/ day for five days. The clinical response to all three therapeutic schemes was satisfactory. The disappearance of malarial symptoms occurred after a maximum 96 hours of treatment, while the assexual parasitaemia clearance occurred within 72 hours, in all therapeutic schemes.
Acesso aberto (Open Access)
Nova proposta de tratamento para malária por Plasmodium vivax
(Universidade Federal do Pará, 1997) ABDON, Nagib Ponteira; SOUZA, José Maria de; http://lattes.cnpq.br/6459204248879587
Relapses that may occur with long standard treatment of vivax malaria might be in part due to an incomplete patient compliance. Therefore, the employment of short treatment schemes leading to a better patient compliance, and the same time having efficacy, tolerance and minimal or none adverse reactions is a matter of serious concern. In order to attain this objective, between july, 1994 to june, 1995, an open, comparative, prospective and randomized study was made in the attendance outpatient unit of Malaria Program of Evandro Chagas Institute, in Belem, Para State. Just patients aged up 12 years, from both sexes, which stayed in Belem during all the period control were enrolled. All patients were from Amazon Region, being the great majority of them from Para (85.8%). Autochthonous cases from the metropolitan area of Belem represented 39.2% of the sample. In this study, 120 patients were divided into 3 groups of 40 patients according to the following therapeutic schemes : Scheme I - chloroquine phosphate tablets with 150 mg of base substance in a total dose of 25 mg / kg / day for 3 days, that is, 10 mg / kg / day in the first day, 7.5 mg / kg / day in the second and third day, plus primaquine phosphate tablets with 15 mg of base substance in a dose of 0.25 mg / kg / day for 14 days. Scheme II - chloroquine phosphate tablets with 150 mg of base substance, 10 mg / kg in a single dose plus primaquine phosphate tablets with 15 mg of base substance in a dose of 0.50 mg / kg / day for 7 days. Scheme III - chloroquine phosphate tablets with 150 mg of base substance, 10 mg / kg in a single dose plus primaquine phosphate tablets with 15 mg of base substance in a dose of 0.50 mg / kg/ day for 5 days. Drugs were administered orally, under medical supervision to all outpatients.Clinical diagnosis was based upon history, epidemiology and physical examination of patients, while the laboratory finding of the hematozoa plasmodium in a thick blood film established the definitive malaria diagnosis. All 3 therapeutic schemes were effective, with a cure rate up to 80%. In the II therapeutic scheme, relapses were not observed. The disappearance of malarial symptoms occurred until 96 hours of treatment, while the assexual parasitaemie clearance occurred until 72 hours, considering all 3 therapeutic schemes. When present, adverse reactions were observed in a short period of time. Even in the cases of primaquine in double dose, there were no toxicity.